Activation of the PI3K/mTOR Pathway Is Involved in Cystic Proliferation of Cholangiocytes of the PCK Rat

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis

(2012) Matthias Evert et al.   HEPATOLOGY

Biliary Infection May Exacerbate Biliary Cystogenesis Through the Induction of VEGF in Cholangiocytes of the Polycystic Kidney (PCK) Rat

(2011) Xiang Shan Ren et al.   AMERICAN JOURNAL OF PATHOLOGY

Targeting mTOR with rapamycin: One dose does not fit all

(2011) David A. Foster et al.   CELL CYCLE

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

(2011) C. Santiskulvong et al.   CLINICAL CANCER RESEARCH

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

(2011) Roman Nawroth et al.   PLoS One

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

(2010) Patrizia Sini et al.   Autophagy

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

The Complexes of Mammalian Target of Rapamycin

(2010) Hongyu Zhou et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys

(2010) Bo Hu et al.   EXPERIMENTAL CELL RESEARCH

Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1

(2010) J. M. Shillingford et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease

(2010) Iram Zafar et al.   KIDNEY INTERNATIONAL

Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats

(2010) C. Renken et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease

(2010) Andreas L. Serra et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

(2010) Gerd Walz et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTORC1 signaling: what we still don't know

(2010) X. Wang et al.   Journal of Molecular Cell Biology

TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2

(2009) J. Copp et al.   CANCER RESEARCH

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice

(2009) Carlo Spirli et al.   HEPATOLOGY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)

(2009) D.-C. Fischer et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Polycystic Kidney Disease

(2008) Peter C. Harris et al.   Annual Review of Medicine

Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease

(2008) C. L. Edelstein   Clinical Journal of the American Society of Nephrology